Handelsbanken Fonder Ab Reata Pharmaceuticals Inc Transaction History

Handelsbanken Fonder Ab

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 02, 2023	SELL	$79.22 - $105.37 $198,050 - $263,425	-2,500 Reduced 30.37%	5,732 $584,000
Q1 2023 Apr 28, 2023	BUY	$30.85 - $93.17 $30,850 - $93,170	1,000 Added 13.83%	8,232 $748,000
Q4 2022 Feb 07, 2023	BUY	$22.15 - $42.11 $160,188 - $304,539	7,232 New	7,232 $275,000
Q4 2021 Feb 08, 2022	SELL	$25.61 - $110.96 $151,099 - $654,664	-5,900 Closed	0 $0
Q2 2021 Aug 03, 2021	BUY	$78.27 - $151.29 $62,616 - $121,032	800 Added 15.69%	5,900 $835,000
Q4 2020 Feb 11, 2021	SELL	$102.03 - $184.62 $183,654 - $332,316	-1,800 Reduced 26.09%	5,100 $630,000
Q3 2020 Nov 13, 2020	SELL	$93.53 - $163.34 $1.87 Million - $3.27 Million	-20,000 Reduced 74.35%	6,900 $672,000
Q2 2020 Aug 13, 2020	BUY	$126.3 - $176.56 $1.63 Million - $2.28 Million	12,900 Added 92.14%	26,900 $4.2 Million
Q1 2020 May 14, 2020	SELL	$124.16 - $247.74 $124,160 - $247,740	-1,000 Reduced 6.67%	14,000 $2.02 Million
Q4 2019 Feb 14, 2020	BUY	$74.57 - $217.92 $1.12 Million - $3.27 Million	15,000 New	15,000 $3.07 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.